Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Toll-Like Receptor-Based Strategies for Cancer Immunotherapy
Saghar Pahlavanneshan, Ali Sayadmanesh, Hamidreza Ebrahimiyan, et al.
Journal of Immunology Research (2021) Vol. 2021, pp. 1-14
Open Access | Times Cited: 72

Showing 26-50 of 72 citing articles:

Immunotherapeutic Implications of Toll-like Receptors Activation in Tumor Microenvironment
Run Zheng, Jian Ma
Pharmaceutics (2022) Vol. 14, Iss. 11, pp. 2285-2285
Open Access | Times Cited: 18
The Role of Cuproptosis Key Factor FDX1 in Gastric Cancer
Qiqi Zhao, Miao Yu, Xueqin Du, et al.
Current Pharmaceutical Biotechnology (2024) Vol. 26, Iss. 1, pp. 132-142
Closed Access | Times Cited: 3
Targeted delivery of pexidartinib to tumor-associated macrophages via legumain-sensitive dual-coating nanoparticles for cancer immunotherapy
Desheng Liang, Wei-Peng You, Fangfang Zhu, et al.
Colloids and Surfaces B Biointerfaces (2023) Vol. 226, pp. 113283-113283
Closed Access | Times Cited: 9
Antitumor Peptide-Based Vaccine in the Limelight
Takumi Kumai, Hidekiyo Yamaki, Michihisa Kono, et al.
Vaccines (2022) Vol. 10, Iss. 1, pp. 70-70
Open Access | Times Cited: 14
Exploring TLR signaling pathways as promising targets in cervical cancer: The road less traveled
Mohini Agarwal, Manish Kumar, Rajiv Pathak, et al.
International review of cell and molecular biology (2024), pp. 227-261
Closed Access | Times Cited: 2
Strategies for Overcoming Immune Evasion in Bladder Cancer
Juhyun Shin, Jeong Youp Park, Seon Wook Kim, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3105-3105
Open Access | Times Cited: 2
Design and evaluation of a multiepitope vaccine for pancreatic cancer using immune-dominant epitopes derived from the signature proteome in expression datasets
Sooram Banesh, Nupoor Patil, Vihadhar Reddy Chethireddy, et al.
Medical Oncology (2024) Vol. 41, Iss. 5
Closed Access | Times Cited: 2
Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis
Kavita A. Iyer, Julian Ivanov, Rumiana Tenchov, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 8519-8544
Open Access | Times Cited: 2
Spherical Nucleic Acids as Precision Therapeutics for the Treatment of Cancer—From Bench to Bedside
Akanksha Mahajan, Alexander H. Stegh
Cancers (2022) Vol. 14, Iss. 7, pp. 1615-1615
Open Access | Times Cited: 13
Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress
Danielle K. DePalo, Jonathan S. Zager
Cancers (2023) Vol. 15, Iss. 5, pp. 1404-1404
Open Access | Times Cited: 7
Toll-Like Receptors and the Response to Radiotherapy in Solid Tumors: Challenges and Opportunities
Ryma Haroun, Sahar Naasri, Ayman Oweida
Vaccines (2023) Vol. 11, Iss. 4, pp. 818-818
Open Access | Times Cited: 6
Chemical reagents modulate nucleic acid-activated toll-like receptors
Xiao Li, Xinyuan Sun, Xuemin Guo, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 147, pp. 112622-112622
Open Access | Times Cited: 10
Toll‑like receptor 3 ligands for breast cancer therapies (Review)
Carly Butkowsky, N. L. Aldor, Sarah J. Poynter
Molecular and Clinical Oncology (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 5
Identification and analysis of the molecular targets of statins in colorectal cancer
Ali Ahmadizad Firouzjaei, Ali Mahmoudi, Wael Almahmeed, et al.
Pathology - Research and Practice (2024) Vol. 256, pp. 155258-155258
Closed Access | Times Cited: 1
Bioinformatics analysis to identify the relationship between human papillomavirus-associated cervical cancer, toll-like receptors and exomes: A genetic epidemiology study
Fabiana de Campos Gomes, Deizyane dos Reis Galhardo, Aline Carvalho Gonçalves Navegante, et al.
PLoS ONE (2024) Vol. 19, Iss. 8, pp. e0305760-e0305760
Open Access | Times Cited: 1
Immunological dynamics in MASH: from landscape analysis to therapeutic intervention
Lawan Rabiu, Pengchao Zhang, Lukman O. Afolabi, et al.
Journal of Gastroenterology (2024) Vol. 59, Iss. 12, pp. 1053-1078
Closed Access | Times Cited: 1
New horizons in cancer immunotherapy: The evolving role of R848 and R837 (Review)
Krupa Bhaliya, Muneera Anwer, Alan L. Munn, et al.
Molecular and Clinical Oncology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Implication of Toll-Like Receptors in growth and management of health and diseases: Special focus as a promising druggable target to Prostate Cancer
Shahanavaj Khan, Rahime Şimşek, Javier David Benítez Fuentes, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024), pp. 189229-189229
Closed Access | Times Cited: 1
Polyethyleneimine-based immunoadjuvants for designing cancer vaccines
Xi Yang, Yuanfeng Wei, Lingnan Zheng, et al.
Journal of Materials Chemistry B (2022) Vol. 10, Iss. 40, pp. 8166-8180
Closed Access | Times Cited: 8
The Role of TRL7/8 Agonists in Cancer Therapy, with Special Emphasis on Hematologic Malignancies
Maria Leśniak, Justyna Lipniarska, Patrycja Majka, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 277-277
Open Access | Times Cited: 4
Role of toll-like receptor in the pathogenesis of oral cancer
Ananya Bhardwaj, Divya Prasad, Sayali Mukherjee
Cell Biochemistry and Biophysics (2023) Vol. 82, Iss. 1, pp. 91-105
Closed Access | Times Cited: 4
The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs
Weijun Pan, Kai Song, Yunli Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma
Christian Karime, Jing Wang, Gregory Woodhead, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 1, pp. 1-13
Closed Access | Times Cited: 9
Bioinformatics Analysis of Novel Targets for Treating Cervical Cancer by Immunotherapy Based on Immune Escape
Ying‐Hao Han, Dongdao Ma, Seung-Jae Lee, et al.
Cancer Genomics & Proteomics (2023) Vol. 20, Iss. 4, pp. 383-397
Open Access | Times Cited: 3
Toll-like receptor-targeted nanoparticles: A powerful combination for tumor immunotherapy
Xin Zhi, Peipei Yang, Yunxue Xu, et al.
Nano Today (2023) Vol. 53, pp. 102003-102003
Closed Access | Times Cited: 3

Scroll to top